Martinez-Castillo M, Altamirano-Mendoza I, Zielinski R, Priebe W, Piña-Barba C, Gutierrez-Reyes G. Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases. World J Clin Cases 2023; 11(6): 1224-1235 [PMID: 36926129 DOI: 10.12998/wjcc.v11.i6.1224]
Corresponding Author of This Article
Gabriela Gutierrez-Reyes, PhD, Academic Research, Professor, Research Scientist, Liver, Pancreas and Motility Laboratory, Unit of Experimental Medicine, School of Medicine, Universidad Nacional Autonoma de Mexico, Hospital General de Mexico, Dr Eduardo Liceaga, Dr. Balmis 148 Col Doctores Cuauhtemoc, Mexico City 06726, Mexico City, Mexico. gabgurey@yahoo.com.mx
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Moises Martinez-Castillo, Itzel Altamirano-Mendoza, Gabriela Gutierrez-Reyes, Liver, Pancreas and Motility Laboratory, Unit of Experimental Medicine, School of Medicine, Universidad Nacional Autonoma de Mexico, Mexico City 06726, Mexico City, Mexico
Moises Martinez-Castillo, Rafal Zielinski, Waldemar Priebe, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, United States
Cristina Piña-Barba, Materials Research Institute, Universidad Nacional Autónoma de México, Mexico City 06726, Mexico City, Mexico
Author contributions: All the authors contributed in the writing and revision of manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gabriela Gutierrez-Reyes, PhD, Academic Research, Professor, Research Scientist, Liver, Pancreas and Motility Laboratory, Unit of Experimental Medicine, School of Medicine, Universidad Nacional Autonoma de Mexico, Hospital General de Mexico, Dr Eduardo Liceaga, Dr. Balmis 148 Col Doctores Cuauhtemoc, Mexico City 06726, Mexico City, Mexico. gabgurey@yahoo.com.mx
Received: October 10, 2022 Peer-review started: October 10, 2022 First decision: October 28, 2022 Revised: November 28, 2022 Accepted: February 2, 2023 Article in press: February 2, 2023 Published online: February 26, 2023 Processing time: 136 Days and 15.6 Hours
Abstract
Approximately 1.5 billion chronic liver disease (CLD) cases have been estimated worldwide, encompassing a wide range of liver damage severities. Moreover, liver disease causes approximately 1.75 million deaths per year. CLD is typically characterized by the silent and progressive deterioration of liver parenchyma due to an incessant inflammatory process, cell death, over deposition of extracellular matrix proteins, and dysregulated regeneration. Overall, these processes impair the correct function of this vital organ. Cirrhosis and liver cancer are the main complications of CLD, which accounts for 3.5% of all deaths worldwide. Liver transplantation is the optimal therapeutic option for advanced liver damage. The liver is one of the most common organs transplanted; however, only 10% of liver transplants are successful. In this context, regenerative medicine has made significant progress in the design of biomaterials, such as collagen matrix scaffolds, to address the limitations of organ transplantation (e.g., low donation rates and biocompatibility). Thus, it remains crucial to continue with experimental and clinical studies to validate the use of collagen matrix scaffolds in liver disease.
Core Tip: The relevance of this review-opinion focuses on new strategies of regenerative medicine and the use of collagen matrix scaffolds as an option in the field of chronic liver disease (fibrosis/cirrhosis and hepatocellular carcinoma). Collagen matrix scaffold can be used as a niche for native or stem cells and as a carrier for antineoplastic drugs; these strategies exhibit the potential to restore liver function and address problems associated with the scarcity of organ donors.
